What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025Blood

Impact of primary CNS prophylaxis in high CNS-IPI DLBCL: Analysis from the czech national lymphoma registry

View Full Paper

Ask AI

Bookmark

Authors

Analysis reveals no significant effect of CNS prophylaxis on progression-free survival in DLBCL patients, suggesting reevaluation of practice.

5-year cumulative incidence of CNS progression was 3.4% in the cohort and 8.8% for high CNS-IPI patients.
Median progression-free survival was better in the IV+/-IT group at 10.99 years compared to 2.99 years.
Observational analysis reviewed treatment outcomes in 1196 patients enrolled in the Czech National Lymphoma Project.
Results imply that intravenous CNS prophylaxis may not be beneficial, highlighting a need for further studies.

Klánová et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Analysis reveals no significant effect of CNS prophylaxis on progression-free survival in DLBCL patients, suggesting reevaluation of practice.